Bayer's Long-Acting Recombinant Factor VIII Demonstrated Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial

The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A BAY 94-9027 helped protect against bleeds when used prophylactically with infusion intervals up to seven days WHIPPANY, N.J., Feb. 1... BiopharmaceuticalsBayer HealthCare Pharmaceuticals, BAY 94-9027, factor VIII, hemophilia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news